No headlines found.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Obsidian Therapeutics trades on the NASDAQ stock market under the symbol OBX.
As of September 4, 2026, OBX stock price declined to $16.82 with 140,105 million shares trading.
OBX has a market cap of $1.04 billion. This is considered a Small Cap stock.
OBX support price is $14.82 and resistance is $19.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OBX shares will trade within this expected range on the day.
